On-Demand Webinar
Reinventing Cardiac Monitoring in Clinical Trials: AI, Safety, and Data Impact
Cardiac monitoring advancements are transforming clinical trials—enhancing data collection and delivery to improve efficiency and accuracy in clinical trials.
Discover the highlights from our fireside chat with leading experts.
Todd Rudo, MD
EVP, Chief Medical Officer
Mark Matson
Senior Director, Sensor Cloud
David E. Albert, MD
Founder, Chief Medical Officer
Insights from the Fireside Chat
TOPIC 1
How Can Patient-Centric Cardiac Monitoring Enable Decentralized and Hybrid Trials?
Recent FDA guidance on digital health technologies and decentralized trials has influenced the greater adoption and implementation of advanced ECG monitoring in clinical research. Explore how patient-centered monitoring advancements support these trial models, delivering real-time data opportunities and optimizing workflows.
TOPIC 2
How Can We Streamline Workflows and Drive Operational Efficiency?
When it comes to data, more is more. Learn how these evolving trial models deliver data that supports advanced AI , streamline data science, and ultimately lead to better outcomes.
TOPIC 3
How Can We Harness AI for More Accurate Data?
AI is revolutionizing the accuracy and efficiency of data analysis in clinical trials. Explore how AI -powered ECG technologies are enhancing data quality and streamlining operations.
Unlock More Insights
Find out how innovative cardiac monitoring solutions can transform your clinical trial with our free guide.
get my guide
Blog
Why Portable 6-Lead Devices Are the Future of Cardiac Monitoring in Clinical Trials
QT determinations are essential in clinical trials, but collecting them is challenging. Discover how the 6-lead device alleviates these challenges for more flexible and patient-centric trials.
Remote Monitoring Boosts Decentralized Trials
PharmExec.com | Decentralized trials are known to have positive effects, but sponsors have concerns about how to monitor patients well. Remote patient monitoring (RPM) solutions, like those from AliveCor, are changing this paradigm. The benefits that decentralized trials offer patients and sponsors are evident. Yet, decentralized trials are still lacking.
JAMA Study Shows a 6-Lead Device Could Reduce the Need to Perform a 12-Lead ECG In Resource Limited Settings
At a QTc interval threshold of 500 milliseconds, the 6-lead device had a high negative predictive value of 99.8% and was an effective triage test. This validation is pivotal for sponsors aiming to deliver quality data while alleviating common cardiac monitoring challenges.